title: Can novel therapeutics halt the amyloid cascade?
abstract: The amyloid hypothesis provides a basis for the development of new therapeutic strategies in Alzheimer's disease. Two large trials have recently been published. The first is a phase 2 study of passive immunotherapy with bapineuzumab, a humanized anti-Abeta monoclonal antibody directed against the N-terminus of Abeta. This trial showed no differences within dose cohorts on the primary efficacy analysis. Exploratory analyses showed potential treatment differences on cognitive and functional endpoints in study completers and apolipoprotein E epsilon4 noncarriers. A safety concern was the occurrence of reversible vasogenic edema. The second study is a phase 3 trial of tarenflurbil, a modulator of the activity of gamma-secretase. Tarenflurbil had no beneficial effect on the primary or secondary outcomes. The tarenflurbil group had a small increase in frequency of dizziness, anemia, and infections. Possible explanations for the negative results of these trials may be related to the study design or the choice of dosage. However, it may also be that these negative findings reflect our still incomplete understanding of, at least part of, the pathogenesis of Alzheimer's disease.
authors.affiliation: Alzheimer Center, VU University Medical Center, Boelelaan 1118, Amsterdam, The Netherlands. nd.prins@vumc.nl.
authors.forename: Niels D
authors.initials: ND
authors.lastname: Prins
authors.forename: Pieter Jelle
authors.initials: PJ
authors.lastname: Visser
authors.forename: Philip
authors.initials: P
authors.lastname: Scheltens
references.citation: Neurology. 2005 May 10;64(9):1553-62
references.pmid: 15883316
references.citation: Stroke. 2006 Sep;37(9):2248-52
references.pmid: 16902173
references.citation: JAMA. 2009 Dec 16;302(23):2557-64
references.pmid: 20009055
references.citation: J Mol Neurosci. 2001 Oct;17(2):259-67
references.pmid: 11816797
references.citation: BMC Neurosci. 2007 Jul 24;8:54
references.pmid: 17650315
references.citation: J Alzheimers Dis. 2009;16(3):601-7
references.pmid: 19276554
references.citation: Neurology. 2009 Dec 15;73(24):2061-70
references.pmid: 19923550
references.citation: Neurology. 2006 Aug 8;67(3):526-7
references.pmid: 16894123
references.citation: Ann Intern Med. 2004 Apr 20;140(8):627-38
references.pmid: 15096334
references.citation: Lancet Neurol. 2010 Apr;9(4):363-72
references.pmid: 20189881
references.citation: J Neurochem. 2009 Aug;110(4):1129-34
references.pmid: 19457065
references.citation: Nat Med. 2000 Aug;6(8):916-9
references.pmid: 10932230
references.citation: Nat Neurosci. 2002 May;5(5):452-7
references.pmid: 11941374
references.citation: Lancet Neurol. 2003 Sep;2(9):539-47
references.pmid: 12941576
references.citation: Lancet Neurol. 2008 Jun;7(6):483-93
references.pmid: 18450517